David-Alexandre Gros MD

David-Alexandre Gros MD General Information

Biography

Mr. David-Alexandre Gros serves as Chief Executive Officer & Board Member at Novus Therapeutics. Dr. Gros, age 48, had been serving as an advisor to Novus since May 2020 and joined Novus from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where since May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. He co-founded and served as Board Member at Eliem Therapeutics. Since November 2018, he has also served on the board of directors of Eliem Pharmaceuticals. He previously served as President and Chief Operating Officer of Neurocrine Biosciences, Inc., from January to December 2017. Beforehand, he was the Senior Vice President, Chief Business Officer and Principal Financial Officer, and was a member of the Management Board of Alnylam Pharmaceuticals, Inc., from June 2015 to January 2017. Prior to joining Alnylam, Dr. Gros served as Executive Vice President and Chief Strategy Officer at Sanofi SA, from September 2011 to June 2015, where he was a member of the Executive Committee. Prior to Sanofi, he held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners from 2009 to 2011 and Merrill Lynch from 2006 to 2009, and in management consulting at McKinsey & Company from 2002 to 2006. Dr. Gros holds an M.D. from The Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School and a B.A. from Dartmouth College.